###begin article-title 0
Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 445 450 <span type="species:ncbi:9606">women</span>
Lung cancer with EGFR mutation was shown to be a specific clinical entity. In order to better understand the biology behind this disease we used a genome wide characterization of loss of heterozygosity and amplification by Single Nucleotide Polymorphism (SNP) Array analysis to point out chromosome segments linked to EGFR mutations. To do so, we compared genetic profiles between EGFR mutated adenocarcinomas (ADC) and KRAS mutated ADC from 24 women with localized lung cancer.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB8</italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HDAC9 </italic>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST1</italic>
###xml 445 452 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 757 764 757 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 779 784 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 848 854 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 858 863 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 884 889 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Patterns of alterations were different between EGFR and KRAS mutated tumors and specific chromosomes alterations were linked to the EGFR mutated group. Indeed chromosome regions 14q21.3 (p = 0.027), 7p21.3-p21.2 (p = 0.032), 7p21.3 (p = 0.042) and 7p21.2-7p15.3 (p = 0.043) were found significantly amplified in EGFR mutated tumors. Within those regions 3 genes are of special interest ITGB8, HDAC9 and TWIST1. Moreover, homozygous deletions at CDKN2A and LOH at RB1 were identified in EGFR mutated tumors. We therefore tested the existence of a link between EGFR mutation, CDKN2A homozygous deletion and cyclin amplification in a larger series of tumors. Indeed, in a series of non-small-cell lung carcinoma (n = 98) we showed that homozygous deletions at CDKN2A were linked to EGFR mutations and absence of smoking whereas cyclin amplifications (CCNE1 and CCND1) were associated to TP53 mutations and smoking habit.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 198 205 198 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
All together, our results show that genome wide patterns of alteration differ between EGFR and KRAS mutated lung ADC, describe two models of oncogenic cooperation involving either EGFR mutation and CDKN2A deletion or cyclin amplification and TP53 inactivating mutations and identified new chromosome regions at 7p and 14q associated to EGFR mutations in lung cancer.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 870 871 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1022 1027 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1093 1100 1093 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(EGFR) </italic>
###xml 1137 1138 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1139 1140 1139 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1338 1343 1338 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1354 1355 1354 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1356 1357 1356 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1573 1574 1573 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
###xml 783 788 <span type="species:ncbi:9606">women</span>
###xml 844 849 <span type="species:ncbi:9606">women</span>
###xml 865 868 <span type="species:ncbi:9606">men</span>
###xml 1052 1059 <span type="species:ncbi:4097">tobacco</span>
###xml 1204 1212 <span type="species:ncbi:9606">patients</span>
###xml 1324 1329 <span type="species:ncbi:9606">women</span>
Lung cancer is the leading cause of cancer-related deaths in the western world [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of the cases and represents a heterogeneous group mainly consisting of adenocarcinoma (ADC), large cell carcinoma (LCC) and squamous cell carcinoma (SCC). The incidence of subtypes has changed in the last decades with increasing incidence of ADC. Moreover, while smoking remains the major risk factor for lung cancer, a subgroup of patients develop lung ADC without smoking history. It is not clear whether lung cancer in non-smokers is increasing in western countries but it is obvious that it has particular clinical and biological features. Population based studies showed that lung cancer in non-smokers occurs preferentially in women with almost 20% of non-smoker lung cancer diagnosed in women versus 2.5% in men [2]. Different studies have shown that genetic abnormalities can be specifically identified in cancer from non-smokers. Indeed we and others showed that KRAS mutations were linked to tobacco consumption whereas EGF receptor (EGFR) mutations were found in non smokers [3-5]. The development of EGFR targeted therapies demonstrated that patients with major clinical response were those that had never smoked, had ADC with bronchioloalveolar component, were women and had EGFR mutations [6-8]. The biology underlying the pathogenesis of the disease may be different from that of smokers and risk factors have not been clearly identified although environmental etiologies are suspected especially in Asians [9]. Transformation of a normal phenotype into a malignant phenotype requires accumulation of multiple genetic and-or epigenetic changes resulting in growth advantage.
###end p 9
###begin p 10
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
The genetic alteration proved to be linked with ADC from non-smokers is the presence of EGFR activating mutations. In order to improve our knowledge of lung cancer biology in non-smokers, one of the first questions to answer is: what are the molecular alterations associated to EGFR mutations in lung cancer?
###end p 10
###begin p 11
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 553 558 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Lung cancer develops as a result of multiple genetic alterations. Loss of heterozygosity (LOH) and gains of chromosome segments are common mechanisms of disease progression. Recently, high-density oligonucleotide-based single polymorphism have been used to quantify chromosome copy number and has been proved to be efficient [10-12]. In an attempt to identify genetic alterations associated with EGFR mutations, we used genome wide SNP assay covering 50000 SNP loci to screen for regions of allelic imbalance (amplified or LOH regions) in a panel of 13 EGFR mutated ADC and 11 non-EGFR mutated ADC.
###end p 11
###begin p 12
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 208 211 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11</italic>
Then, in a second part, we focused on cell cycle genes that were found to be differentially involved between groups and screened a large series of 98 NSCLC for genetic alterations at CCND1, CCNE1, CDKN2A and RB1. Alterations were studied according to other known mutations (EGFR, ERBB2, BRAF, KRAS, TP53 and STK11). This work led to the characterization of two different models of oncogenic cooperation one linked to smoking and the other not. Moreover, we identified four chromosome regions at 14q and 7p specifically amplified in EGFR mutated ADC.
###end p 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 13
###begin p 14
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 401 405 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB3</italic>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 507 514 <span type="species:ncbi:9606">Patient</span>
###xml 848 853 <span type="species:ncbi:9606">women</span>
Patients with primary lung cancers were enrolled in this study according to French laws and have been previously described [4]. Briefly, patients had surgery for non-small cell lung cancer, no neoadjuvant treatment and were managed to the Georges Pompidou European Hospital in Paris, France from 2003 to 2004. All tumors but numbers 134, 135, 177 and 246 had been characterized for mutations in EGFR, KRAS, BRAF, ERBB2, ERBB3, PIK3CA, TP53 and STK11 [4]. STK11 mutations have not been previously published. Patient characteristics are summarized in Table 3. DNAs were extracted after pulverization in liquid nitrogen and protein kinase digestion using Qiamp tissue kit (Qiagen, Les Ulis, France). Twenty-four DNAs (13 with classic EGFR mutations, 11 without) and 6 non-tumor DNAs were selected for SNP array analysis. All tumors selected were from women.
###end p 14
###begin title 15
Single Nucleotide Polymorphism Array Analysis
###end title 15
###begin p 16
###xml 8 12 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Genechip(R) Mapping 50K-Xba array was used for this analysis. Preparation of DNA targets, labelling, hybridization, washing, staining and scanning was done according to the manufacturer's instructions (Affymetrix, UK) by PartnerChip (Evry, France).
###end p 16
###begin p 17
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Data were analyzed using Copy Number Analyser for Affymetrix Gene Chip Mapping (CNAG 2.0) software [13]. We selected randomly 18 independent subjects from Mapping 100k HapMap Trio Dataset provided by affymetrix. Indeed, this software/algorithm uses a set of normal reference individuals and do not require the use of a paired normal sample to perform the analysis.
###end p 17
###begin p 18
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Data from CNAG were export in aCGH sotfware (R package) that was used for plot performance and statistical comparison of EGFR mutated and non-mutated tumors.
###end p 18
###begin title 19
Quantitative PCR experiments
###end title 19
###begin p 20
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 215 218 215 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSA</italic>
###xml 706 711 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1</italic>
###xml 720 727 720 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 731 734 731 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSA</italic>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 810 813 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC</italic>
###xml 815 820 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DSG2 </italic>
###xml 824 829 824 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DSC3 </italic>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HDAC9</italic>
###xml 874 881 874 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST1 </italic>
###xml 885 891 885 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB8 </italic>
###xml 1088 1089 1088 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 194 199 <span type="species:ncbi:9606">Human</span>
Validation of homozygous deletions (CDKN2A) and regions with focal amplification (CCND1 and CCNE1) was done on the 24 tumors screened by SNP array and extended to a total of 98 NSCLC (Table 2). Human serum albumin (HSA) was used as the reference gene. DNA concentrations were determined using ND-1000 spectrophotometer Nanodrop technology and were normalized to 12,5ng/ul. Real time quantitative PCR using TaqMan probes was performed using an ABI Prism 7900 sequence detection system (Applied Biosystems, Courtaboeuf, France) with the software program SDS 2.0 (Applied Biosystems). Each assay was run on a 384 plate, tumor DNAs, normal controls (n = 6) and no template controls were run in triplicates for CCND1, CCNE1, CDKN2A and HSA. Primers and probes were described elsewhere [14]. Homozygous deletions at DCC, DSG2 and DSC3 as well as copy number changes of the HDAC9, TWIST1 and ITGB8 region were validated by real time PCR for the 24 tumors screened by SNP array. Primers and probes where designed with Primer Express 2.0 software program (Applied Biosystems) (see Additional file 1). All primers were purchased from Operon (Cologne, Germany) and probes from Applied Biosystems.
###end p 20
###begin p 21
###xml 118 119 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 364 367 337 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSA</italic>
###xml 512 526 481 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
The PCR mix consisted of ABsolutetrade mark QPCR MIX 1x (ABgene, Courtaboeuf, France), primers 300 nM, probe 200 nM, H20 and 25 ng of DNA template in a final volume of 10 ul. Cycling condition were denaturation 95degreesC for 15 min and 40 cycles of 95degreesC, 15 sec followed by 60degreesC, 15 sec. Quantification was done by normalizing the results to those of HSA. The normalized amount of gene in tumor samples was determined by designating the average of DeltaCt of 6 non-tumor tissues as calibrator. 2 x 2-DeltaDeltaCt represented an estimation of the number of gene copy in tumor tissues.
###end p 21
###begin p 22
###xml 26 40 26 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 81 95 71 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
The cutoff value was 2 x 2-DeltaDeltaCt </= 0.6 for homozygous deletion and 2 x 2-DeltaDeltaCt >/= 4 for amplifications.
###end p 22
###begin title 23
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
STK11 Mutations screening
###end title 23
###begin p 24
Exons 1 to 9 were screened by direct sequencing. Primers used for the amplification and sequencing of each exon and intron-exon junctions and PCR conditions are available upon request.
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Fractional allelic loss (FAL) and fractional allelic amplification (FAA) were calculated for each tumor as the number of chromosome arms with either loss of heterozygosity or amplifications divided by the number of chromosome arms tested (41). Mean FAL and FAA were compared using student T test. Qualitative variables were compared using chi square test or Fisher exact test when necessary. All tests were performed using STATA 7.0 (StataCorp LP, College Station, TX) aCGH software was used to test the existence of meaningful differences between focal chromosome alterations in EGFR mutated and non-mutated tumors. False discovery rate test (FDR) has been used to assess p values. FDR represents the expected percentage of false positive among the claimed positive and estimates global error for multiple testing situations. Therefore p values were adjusted to the number of tests performed.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Array global analysis
###end title 28
###begin p 29
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
Mapping genome wide chromosomal alterations in EGFR mutated lung ADC (n = 13) versus non-mutated ones (n = 11) had two different objectives. First, a global comparison of allelic imbalances and second, a targeted analysis of specific loci to point out genes implicated in the oncogenesis of one subtype or the other. It is to note that, in an effort to homogenize both groups, non-EGFR mutated ADC are all KRAS mutated. Fractional allelic loss (FAL) and fractional allelic amplification (FAA) were calculated as the number of chromosome arm with LOH or amplified loci divided by 41 chromosome arms.
###end p 29
###begin p 30
###xml 80 85 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 93 98 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 228 233 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 307 312 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 421 426 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 462 467 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 481 483 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 488 490 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
Mean FALs were equal to 0.16 (+/- 0.08) and 0.09 (+/- 0.05), (p = 0.024) in the EGFR and the KRAS mutated group respectively. Chromosome arms that were involved in LOH (copy number </= 1) in more than 25% of tumors were, in the EGFR mutated group 6q, 7q, 8p, 9p, 10q, 12p, 12q, 13q, 15q and 18q, and in the KRAS mutated group 3q, 5q, 8p and 19p. A single copy of chromosome 9, 13, 15, 18 and 22 was found in at least one EGFR tumor, no monosomy was found in the KRAS group (Figure 1a and 1b).
###end p 30
###begin p 31
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNA copy number alterations by SNP array analysis. </bold>
DNA copy number alterations by SNP array analysis.  Figure 1 represents the fraction of the samples with copy number amplification of at least three copies (green) and copy number reduction (red) across all chromosome SNPs; in the EGFR non-mutated/KRAS mutated group (A) and the EGFR mutated/ KRAS non-mutated group (B). (C) Statistical comparison of both groups showing regions of amplification 20 statistically linked to EGFR mutated tumors (black arrows). False discovery rate (FDR) has been used to estimate global error for multiple testing situations.
###end p 31
###begin p 32
###xml 107 112 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 123 128 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 296 301 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 352 357 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 379 381 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 386 388 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
Concerning amplifications, mean FAAs were equal to 0.50 (+/- 0.19) and 0.33 (+/- 0.24), (p = 0.039) in the EGFR versus the KRAS mutated group. Chromosome that had amplified regions (copy number >/= 3) at high rates (> 50% of tumors) were 1p-q, 2p, 3q, 5q, 7p-q, 8q, 14q, 17q, 21q and Xp-q in the EGFR mutated group and 1q, 2p-q, 5p, 8q and Xp-q in the KRAS mutated group (Figure 1a and 1b).
###end p 32
###begin title 33
Array targeted analysis
###end title 33
###begin p 34
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 749 763 749 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HDAC9, TWIST1 </italic>
###xml 767 773 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB8 </italic>
###xml 872 878 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HDAC9 </italic>
###xml 882 888 882 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB8 </italic>
###xml 1039 1044 1039 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1142 1147 1142 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1187 1192 1187 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
Differential analysis between EGFR mutated and KRAS mutated tumors using aCGH package [15] showed that one region at 14q (p = 0.027) and three regions at 7p (p = 0.032, p = 0.042, p = 0.043) were statistically more frequently amplified in the EGFR group (Figure 1c). Detailed statistic analysis is shown as supplementary data (see Additional file 2). Genes located in these regions are given in Table 1. The gene located at 14q is a MAM domain protein. The MAM domain is present in many cell surface proteins and is thought to be involved in cell-cell adhesion, protein-protein interactions, and signal transduction, whether this protein could be linked to carcinogenesis remain to be studied [16]. Of the ones located at 7p21.1, it is to note that HDAC9, TWIST1 and ITGB8 are potential targets. Gene copy numbers at 7p21.1 were validated by quantitative PCR using probes HDAC9 and ITGB8 in the 24 tumors and 7 cell lines were tested for copy number changes using same probes (Calu6-H460-A549-H1299-H1650-H1975-H358), both cell lines with EGFR mutation were found amplified (H1650-H1975) versus one out of five without EGFR mutations (H358). EGFR is located at 7p11.2, among tumors with EGFR mutations, one has no copy number alteration at 7p, 9 showed concomitant 7p11.2 and 7p21.1 amplifications (>3) and 3 had a localized amplification, 2 at 7p21.1 and 1 at 7p11.2. EGFR amplifications were not statistically related with EGFR mutation but 5/13 in the EGFR group versus 1/11 in the KRAS group had estimated copy number > 4.
###end p 34
###begin p 35
Shows regions of focal amplifications analyzed by Xba1 50000 SNPs array (Affymetrix) that are significantly linked to EGFR mutated tumors.
###end p 35
###begin p 36
Regardless of statistical difference between the two groups, focal amplifications and homozygous deletion are of special interest as they may indicate oncogenes or tumor suppressors. Recurrent regions of deletions and focal amplifications were defined as segments of at least 5 SNP loci in more than 2 tumors.
###end p 36
###begin p 37
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AFF3</italic>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LAF4</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRC1</italic>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNW1</italic>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF7</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPL </italic>
###xml 336 343 336 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTAGE1 </italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYST3</italic>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBKB</italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK4 </italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL9</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF10</italic>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL31RA</italic>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLK2</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WISP1</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTERT</italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EFGR</italic>
###xml 554 557 554 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
A total of 58 regions with focal amplification were identified. Among them 22 regions were found exclusively in EGFR mutated tumors versus 2 in KRAS mutated tumors. Genes potentially involved in carcinogenesis located in these regions are listed as supplementary material (see Additional file 3), AFF3, LAF4, LRRC1, SNW1, FGF7, PPL and CTAGE1 for EGFR mutated tumors and MYST3, IKBKB, DKK4 for KRAS mutated tumors. Regions of amplifications common to both groups delineated by the SNP array included BCL9, FGF10, IL31RA, PLK2, WISP1, HTERT, CCND3, EFGR, MYC.
###end p 37
###begin p 38
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC</italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 527 531 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DSG3</italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DSC2 </italic>
###xml 542 546 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC </italic>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
Homozygous deletions were identified at chromosome regions 2q36.3, 9p21.1, 12q13.13, 18q12.1 and 18q21.2. The 9p21.1 locus contains CDKN2A and the 18q21.1 contains DCC, both are well known tumor suppressors. Genes in the 12q13.13 and 2q36.3 regions have not been linked to cancer up to now and the 18q12.1 region contains a cluster of genes coding desmosomal proteins. All homozygous deletions were found in the EGFR mutated group (Table 2). For the 24 tumors, quantitative PCR was ran to estimated gene copy number at CDKN2A, DSG3, DSC2 and DCC and validated the results of the SNP Array (see Additional file 4).
###end p 38
###begin p 39
Regions of homozygous deletions identified by SNP array in this series.
###end p 39
###begin p 40
Homozygous deletion were validated by real time quantitative PCR for CDKN2A, DCC, DSC3 and DSG2.
###end p 40
###begin title 41
Cell cycle related genes and lung carcinogenesis
###end title 41
###begin p 42
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 419 426 419 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 638 643 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 843 847 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 899 906 899 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 928 934 928 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 938 944 938 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 1126 1131 1126 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 1133 1139 1133 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 1141 1145 1141 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 1147 1152 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 1156 1162 1156 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 1201 1207 1201 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 1210 1216 1210 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 1283 1290 1283 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1354 1355 1354 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The presence of CDKN2A homozygous deletion was restricted to the EGFR group and concerned 3 tumors out of 13 while LOH at this locus was present in 4 EGFR mutated tumors versus 2 non-mutated ones. Furthermore, since LOH at RB1 was restricted to EGFR mutated tumors we made the hypothesis that alterations of the G1-S check point could be different in EGFR mutated tumors as compared to non-mutated ones. Differences at CDKN2A and RB1 did not reach statistical significance at the array level however it deserved to be confirmed in a larger series of NSCLC and enlarge to other key regulators as cyclins. LOH at RB1 locus clustered to the EGFR group, therefore we screened the entire coding sequence and exon-intron boundaries for alterations in the subgroup of 13 EGFR mutated tumors. As no mutation was identified in this subgroup of tumors, RB1 sequencing was not done on the entire series. Then, CDKN2A homozygous deletions, CCNE1 and CCND1 amplifications were analyzed by real time quantitative PCR on a series of 98 NSCLC including the 24 tumors previously typed by SNP array. All tumors had been characterized for EGFR, ERBB2, PIK3CA, BRAF, KRAS and STK11 mutations. Briefly, 13 and 6 NSCLC had CCND1 or CCNE1 amplification respectively and 8 tumors had homozygous deletion at CDKN2A locus including the 3 previously found in array analysis (Table 3).
###end p 42
###begin p 43
Describes the population studied in terms of clinico-pathological features, gene mutations (EGFR, ERBB2, PIK3CA, KRAS, BRAF and TP53) as well as gene copy number (CCND1, CCNE1 and CDKN2A) analyzed by real time PCR.
###end p 43
###begin p 44
For quantitative PCR, an inferred copy number >/= 4 defines an amplification of target and an inferred copy number </= 0.6 defines homozygous deletion. Tumors analyzed by Xba1 50000 SNPs array (Affymetrix) are underlined.
###end p 44
###begin title 45
Relation between cyclin amplification and clinicopathological parameters
###end title 45
###begin p 46
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 68 75 <span type="species:ncbi:4097">tobacco</span>
A significant association was found between CCND1 amplification and tobacco exposure (p = 0.023) and TP53 mutations were linked to CCNE1 (p = 0.006), or CCND1 (p = 0.048) amplifications (Table 4). One tumor showed simultaneous amplification of both cyclins.
###end p 46
###begin p 47
Statistical analysis: CCND1, CCNE1, CDKN2A associations with clinico-pathological features and other gene alterations.
###end p 47
###begin p 48
 In this work we called PI3K-AKT-mTOR activated tumors, tumors with either EGFR, PIK3CA, ERBB2 or STK11 mutation*.
###end p 48
###begin title 49
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
Relation between CDKN2A homozygous deletion and clinicopathological parameters
###end title 49
###begin p 50
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 149 156 149 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 241 248 241 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 403 410 403 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 512 519 512 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 105 112 <span type="species:ncbi:4097">tobacco</span>
CDKN2A homozygous deletions were significantly associated with EGFR mutations (p = 0.002) and absence of tobacco exposure (p = 0.012). One tumor had CDKN2A homozygous deletion and CCNE1 amplification (Table 4). Three tumors from smokers had CDKN2A homozygous deletion, one had a STK11 and the other a PIK3CA mutation. It suggested that an activation of the EGFR/PI3K/AKT/mTOR pathway could be linked to CDKN2A homozygous deletion in lung cancer regardless of smoking status. All together, 8 tumors out of 9 with CDKN2A homozygous have EGFR/PI3K/AKT/mTOR pathway alterations.
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 802 807 802 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 902 907 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1380 1382 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1651 1653 1651 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 605 610 <span type="species:ncbi:9606">women</span>
###xml 666 671 <span type="species:ncbi:9606">women</span>
###xml 944 951 <span type="species:ncbi:4097">tobacco</span>
###xml 960 967 <span type="species:ncbi:4097">tobacco</span>
In lung cancer, EGFR inhibitors have been shown to be efficient in tumors with activating mutations of the receptor. This molecular alteration defines a subgroup of patients with specific clinicopathological features. The most striking one is the fact that patients are mostly non-smokers. Understanding the carcinogenesis pathway that drives lung carcinogenesis in non-smokers is therefore of major interest. The present work represents the first comparative study of genome wide allelic imbalance between EGFR mutated lung ADC and KRAS mutated ADC. In our work, EGFR mutated tumors are from non-smoking women with ADC, the control group was selected among smoking women with ADC and without EGFR mutations. As most of them have KRAS mutations, we chose to consider for the SNP array only tumors with KRAS mutations in order to have a homogenous control group. Moreover, it was already suggested that KRAS and EGFR mutations were hallmarks of tobacco and non-tobacco induced lung carcinogenesis [17]. Different reports showed that SNP array technology provided the opportunity to assess DNA copy number and LOH through the entire genome [12,18-20]. The overall pattern of alterations seen in this study is reliable with previous lung ADC studies. As already noted, frequent chromosome gains are found at 1q, 5p, 7p/q, 8q and 14q and losses at 6q, 8p, 9p, 13q, 18q and 19p [11,20-22]. But new regions of homozygous deletion have been found in EGFR mutated tumors especially at 18q involving the DCC gene and a cluster of desmosomal proteins. New regions of focal amplification at 7p and 14q have also been delineated that encodes potential oncogenes [22].
###end p 52
###begin p 53
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Using this technology, we showed that genome wide allelic imbalance patterns are different in tumors from non-smokers when compared to that of smokers. Indeed, more LOH and amplified regions were found in the EGFR mutated group when considering either all regions > 5 SNPs or entire chromosome arm losses or amplifications. This fact has already been suggested in a previous work using microsatellite markers and showing that tumors in non-smokers had more alterations than that of smokers [23]. The mechanisms leading to this increased chromosomal instability is not yet understood. In this series TP53 mutations were equally distributed in both groups therefore the impact of TP53 on genome stability cannot be discussed. Other mechanism such as repair defects could be involved in increased chromosomal instability in non-smokers.
###end p 53
###begin p 54
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 456 461 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 524 529 524 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTK7 </italic>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HMOX2 </italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1301 1306 1301 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1490 1497 1490 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1522 1528 1522 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNE1 </italic>
###xml 1560 1562 1560 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1589 1596 1589 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1682 1684 1682 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1711 1718 1711 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1747 1752 1747 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 1869 1876 1869 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1901 1905 1901 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 1907 1913 1907 1913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 1916 1923 1916 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 2038 2044 2038 2044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 2320 2327 2320 2327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 2380 2387 2380 2387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 2467 2477 2467 2477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/p16</italic>
###xml 2535 2542 2535 2542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14/ARF</italic>
###xml 2754 2759 2754 2759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 2786 2792 2786 2792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 2842 2857 2842 2857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/p14/ARF </italic>
###xml 2915 2920 2915 2920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 2924 2930 2924 2930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 2953 2955 2953 2955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 3169 3177 3169 3177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14/ARF </italic>
###xml 3218 3225 3218 3225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 3269 3274 3269 3274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 3350 3357 3350 3357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 3377 3384 3377 3384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 3503 3505 3503 3505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 3529 3544 3529 3544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/p14/ARF </italic>
###xml 3755 3762 3755 3762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 3992 3997 3992 3997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 4010 4017 4010 4017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 4046 4048 4046 4048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 4049 4051 4049 4051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 4130 4135 4130 4135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 4228 4233 4228 4233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 4318 4324 4318 4324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1 </italic>
###xml 4328 4333 4328 4333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 4387 4389 4387 4389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 3667 3675 <span type="species:ncbi:9606">patients</span>
###xml 4104 4111 <span type="species:ncbi:4097">tobacco</span>
In parallel to DNA assays, RNA expression profiles also demonstrated differences between ADC from smokers when compared with non-smokers [24,25]. In a recent paper dealing with expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung cancer two groups of ADC were individualized, one being a bronchial-type, the other an alveolar-type [26]. Unsupervised classification failed to detect any specific group of tumors that had EGFR mutations but they showed 26 genes preferentially expressed in EGFR mutated group. Among them, three genes EGFR, PTK7 and HMOX2 were found in our series located in focal regions of amplifications. Finally, a genetic classification of lung ADC by CGH array showed that EGFR mutated tumors could be individualized as a specific cluster [27]. All together, these results tend to prove that lung ADC in non-smokers forms a distinct disease at least at a molecular point of view. SNP arrays allow the identification of many loci with either LOH or amplification. Some of which may represent background alterations with no specific involvement in the carcinogenesis process. The identification of regions that are critical for tumor cell proliferation is of major importance. In order to go further in the identification of alterations linked to EGFR mutations we focused on genes implicated in cell cycle regulation and validated SNP array information on a large series of NSCLC. Previous genome analysis using SNP Arrays also showed CDKN2A homozygous deletions and CCNE1 amplifications in lung cancers [12]. We found a link between CDKN2A homozygous deletion and the non-smoking status as already suggested by Kraunz et al. [28]. Moreover, in our series CDKN2A deletion was associated with EGFR mutation and maybe with an activation of the EGFR/PI3K/AKT/mTOR transduction pathway. Indeed, 7 out of 8 tumors with CDKN2A homozygous deletion have EGFR, STK11 or PIK3CA mutations. Activation of this signal transduction pathway can lead to enhance transcription of cell cycle genes as CCND1 and it is not surprising that no cyclin amplification was observed in this group. For this group of tumors, it seems that proliferation is under the dependence of an activation of cell cycle through EGFR/PI3K/AKT/mTOR signaling and an inactivation of the cell cycle inhibitor CDKN2A preventing cells to down-regulate proliferation. The CDKN2A locus at 9p21 encodes two genes, one inhibits CDK4 mediated RB phosphorylation (CDKN2A/p16) and the other binds MDM2 leading to TP53 stabilization (p14/ARF). qPCR experiments reported here, analyzed homozygous deletions at 9p21 and therefore co-deletion of both genes. A recent paper showed that the p14/ARF protein was frequently down regulated in lung cancers with EGFR mutation or in tumors with ERBB2 mutations. As in our work, down regulation of the CDKN2A/p14/ARF locus could be linked to PI3K/AKT/mTOR activation as both EGFR and ERBB2 activate this pathway [29]. Although, regarding our results, it is very surprising that in their experiments, CDKN2A expression measured by immunohistochemistry remained positive when p14/ARF expression was extinguished. It suggested that p14/ARF could be down regulated independently of CDKN2A by mutation or promoter hypermethylation in EGFR mutated tumors. Promoter hypermethylation has indeed been shown to turn off CDKN2A locus in cancer but CDKN2A hypermethylation was linked to heavy smoking and squamous cell cancer which represents a different subgroup of tumors [30]. Here we suggest that CDKN2A/p14/ARF locus homozygous deletion could be an alternative mechanism to down regulate cell cycle inhibitors in ADC from non-smoking patients. In our series, Illumina GoldenGate Assay for methylation was used to quantify CDKN2A methylation, in the 24 tumors analyzed by SNP array. No difference in methylation status was found between EGFR, KRAS mutated tumors and non-tumor tissues (data not shown). Two other papers reported a negative correlation between EGFR mutation and CDKN2A methylation status in NSCLC [31,32]. Cyclin amplifications were in opposite related to tobacco and associated to TP53 mutations. In this case, cell cycle is activated through direct amplification of cyclins and TP53 inactivating mutations unable cells to repress proliferation. An association between CCND1 and TP53 was already suggested by protein expression analysis [33].
###end p 54
###begin p 55
###xml 408 413 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 264 271 <span type="species:ncbi:4097">tobacco</span>
Although these models are not to generalize since other mechanisms such as mutations epigenetic alteration and protein overexpression can activate oncogene or inactivate tumor suppressor, our work enlightened two different carcinogenesis pathways in NSCLC. One is tobacco independent and driven by CDKN2A inactivation and EGFR mutations, the other is smoking dependent and driven by cyclin amplification and TP53 mutation (Figure 2).
###end p 55
###begin p 56
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Represents two possible models of oncogenic cooperation in smokers </bold>
Represents two possible models of oncogenic cooperation in smokers (A) (Cyclin amplification associated with TP53 mutations) and in non-smokers (B) (EGFR mutation associated with CDKN2A homozygous deletion)
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 560 567 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
Although this work concerned a limited series of tumors, we focused on a comparative analysis and showed that patterns of genome wide genetic alterations are different between ADC with and without EGFR mutation. More alterations and a higher frequency of large alterations (entire chromosome arms deletion or amplification) were found in the EGFR mutated group suggesting that carcinogenesis pathways are different. Indeed, for a subset of tumors specific involvement of cell cycle genes were identified and an oncogenic cooperation between EGFR mutations and CDKN2A homozygous deletion was identified.
###end p 58
###begin title 59
Abbreviations
###end title 59
###begin p 60
ADC: Adenocarcinoma; LCC: Large Cell Carcinoma; SCC: Squamous Cell Carcinoma; BAC: Bronchioloalveolar carcinoma.
###end p 60
###begin title 61
Competing interests
###end title 61
###begin p 62
The authors declare that they have no competing interests.
###end p 62
###begin title 63
Authors' contributions
###end title 63
###begin p 64
HB: Study design, analysis of the data, redaction of the manuscript. KP: quantitative PCR experiments, sequencing of target genes, analysis of the data. DLC: DNA extraction sequencing of target genes. CD: Study design, Pathological examination of the specimen. MT: quantitative PCR experiments. CH: sequencing of target genes. EF-G: Study design, collection of clinical data associated with tumor specimen. MR: Study design, collection of clinical data associated with tumor specimen. PD: Analysis of the data and redaction of the manuscript. PL-P: Study design, analysis of the data, redaction of the manuscript.
###end p 64
###begin title 65
Pre-publication history
###end title 65
###begin p 66
The pre-publication history for this paper can be accessed here:
###end p 66
###begin p 67

###end p 67
###begin title 68
Supplementary Material
###end title 68
###begin title 69
Additional file 1
###end title 69
###begin p 70
Provides a list of probes and primers used in the study for qPCR experiments.
###end p 70
###begin p 71
Click here for file
###end p 71
###begin title 72
Additional file 2
###end title 72
###begin p 73
Shows detailed statistical analysis using aCGH package. p was corrected for multiple testing situations. One region at 14q and three regions at 7p show meaningful differences between EGFR mutated and non-mutated tumors.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Additional file 3
###end title 75
###begin p 76
Shows regions of focal amplifications analyzed by Xba1 50000 SNPs array (Affymetrix) in EGFR mutated and KRAS mutated tumors independently of statistical differences. Genes, written in bold, have potential or obvious involvement in cell growth. For regions counting more than 10 genes only genes likely to have a role in carcinogenesis are given.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional file 4
###end title 78
###begin p 79
Shows the comparaison between the copy number estimated by the 50K SNP Array and qPCR.
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Acknowledgements
###end title 81
###begin p 82
We thank La Ligue Nationale de Lutte Contre le Cancer, l'Institut National du Cancer (INCA) and le Canceropole Ile de France for their support.
###end p 82
###begin article-title 83
Cancer statistics, 2007
###end article-title 83
###begin article-title 84
Lung cancer incidence in never smokers
###end article-title 84
###begin article-title 85
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung
###end article-title 85
###begin article-title 86
Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation
###end article-title 86
###begin article-title 87
###xml 98 103 <span type="species:ncbi:9606">women</span>
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women
###end article-title 87
###begin article-title 88
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
###end article-title 88
###begin article-title 89
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
###end article-title 89
###begin article-title 90
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
###end article-title 90
###begin article-title 91
Epidemiology of lung cancer
###end article-title 91
###begin article-title 92
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays
###end article-title 92
###begin article-title 93
###xml 106 111 <span type="species:ncbi:9606">human</span>
High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines
###end article-title 93
###begin article-title 94
###xml 54 59 <span type="species:ncbi:9606">human</span>
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
###end article-title 94
###begin article-title 95
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays
###end article-title 95
###begin article-title 96
###xml 146 153 <span type="species:ncbi:9606">patient</span>
Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome
###end article-title 96
###begin article-title 97
The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu
###end article-title 97
###begin article-title 98
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
###end article-title 98
###begin article-title 99
High-resolution analysis of DNA copy number using oligonucleotide microarrays
###end article-title 99
###begin article-title 100
Single nucleotide polymorphism array analysis of cancer
###end article-title 100
###begin article-title 101
Allele-specific amplification in cancer revealed by SNP array analysis
###end article-title 101
###begin article-title 102
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering
###end article-title 102
###begin article-title 103
Characterizing the cancer genome in lung adenocarcinoma
###end article-title 103
###begin article-title 104
Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers
###end article-title 104
###begin article-title 105
###xml 18 23 <span type="species:ncbi:9606">human</span>
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
###end article-title 105
###begin article-title 106
Gene expression in lung adenocarcinomas of smokers and nonsmokers
###end article-title 106
###begin article-title 107
Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma
###end article-title 107
###begin article-title 108
Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features
###end article-title 108
###begin article-title 109
###xml 38 45 <span type="species:ncbi:4097">tobacco</span>
Homozygous deletion of p16(INK4a) and tobacco carcinogen exposure in nonsmall cell lung cancer
###end article-title 109
###begin article-title 110
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history
###end article-title 110
###begin article-title 111
The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance
###end article-title 111
###begin article-title 112
Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
###end article-title 112
###begin article-title 113
Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers
###end article-title 113
###begin article-title 114
Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome
###end article-title 114

